Almanac A1C

Why Omega-3s Fail to Deliver: The Hidden Biology Behind a Good Idea Gone Wrong

Posted

by

dr. Karunia Valeriani Japar

Table of Contents
Keywords: , , , ,

The Omega-3 Paradox

Omega-3 polyunsaturated fatty acids (PUFAs), particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have long been promoted as key nutrients for cardiovascular, cognitive and systemic health. Epidemiological observations in populations with high seafood consumption such as Greenland Inuit and coastal Japanese communities, initially suggested strong cardioprotective and anti-inflammatory benefits associated with higher omega-3 Intake (Dyerberg& Bang, 1982; Mozaffarian & Wu, 2011). These findings encouraged widespread supplementation, turning omega-3, capsules into one of the most consumed nutraceuticals globally, often perceived as a near-universal wellness solution.

Despite extensive mechanistic evidence supporting their biological relevance, ranging from anti-inflammatory lipid mediator production to membrane fluidity modulation, the clinical outcomes have been inconsistent. Large-scale randomized trials, such as the VITAL and STRENGTH studies, have failed to demonstrate significant risk reduction for major cardiovascular events among generally healthy or statin-treated individuals (Manson et al., 2019; Nichols et al., 2020). Even among health-conscious consumers and those with elevated triglycerides, subjective or measurable benefits, such as improved cognition, lipid metabolism or inflammatory markers, often remain elusive.

This discrepancy between promising biochemical theory and disappointing clinical reality forms what may be called the “omega-3 paradox.” That is, omega-3 supplementation appears mechanistically flawless yet physiologically underwhelming when applied at scale. Understanding why, whether due to context, formulation, metabolic environment, or molecular interactions is essential to redefining how omega-3s should be integrated into preventive medicine and longevity strategies.

The Original Promise: Mechanisms That Should Work

Omega-3 polyunsaturated fatty acids exert multiple biologically plausible effects that initially positioned them as compelling candidates for cardiovascular and neuroprotective therapy. Incorporation of EPA and DHA into phospholipid bilayers alters membrane fluidity and lipid raft organization, thereby modulating receptor function, ion channel behavior, and downstream signaling in endothelial, neuronal and immune cells. At the same time, omega-3 derived specialized pro-resolving mediators (SPMs) including resolvins, protectins, maserins actively terminate inflammation, enhance efferocytosis, and promote tissue repair, shifting the inflammatory response from chronic activation toward controlled resolution. Beyond their roles in membranes and immune signaling, omega-3 fatty acids influence lipid metabolism by lowering triglyceride levels and have been shown in experimental and translational work to support mitochondrial integrity, reduce reactive oxygen species generation, and stabilize mitochondrial membrane potential in metabolically active tissues [1,2,3,4,5,6].

These mechanistic insights appeared to align well with epidemiological observations in populations with high marine food intake, where increased consumption of fatty fish correlated with lower rates of sudden cardiac death and coronary events. The development of the omega-3 index, reflecting erythrocyte EPA and DHA content, further reinforced this narrative by demonstrating inverse associations between higher omega-3 status, cardiovascular risk, and all-cause mortality in observational cohorts. Coastal and seafood-rich communities, which typically exhibit higher omega-3 indices that inland populations, have often been cited as natural experiments supporting the cardiometabolic benefits of sustained omega-3 exposure. Taken together, the convergence of cellular mechanisms, mitochondrial effects, and epidemiological data created a strong rationale for omega-3 supplementation as a preventive strategy in cardiometabolic and neurodegenerative disease [2,3,7,8,9,10].

Yet, when these mechanistic promises are tested in large randomized controlled trials and routine clinical practice, the anticipated magnitude and consistency of benefit frequently fail to materialize. This growing disconnects between biochemical plausibility, encouraging population signals, and underwhelming intervention outcomes raises a critical question for preventive medicine and longevity research: if the mechanisms are so compelling, why does the research so often struggle to translate into robust, reproducible clinical results?

The Bioavailability Problem: When Supplementation ≠ Cellular Uptake

The efficacy of omega-3 interventions hinges on fundamental yet often overlooked variable: bioavailability most commercial omega-3 concentrates are processed into ethyl ester (EE) forms to achieve higher concentrations of EPA and DHA during molecular distillation. While chemically stable, these ethyl esters are essentially “pro-drugs” that require efficient hydrolysis by pancreatic lipase to release the free fatty acids for absorption. In the absence of high-fat meal to stimulate bile salt secretion and pancreatic enzyme activity, the absorption of ethyl esters is notoriously poor, often as much as 50% lower than that of the natural triglyceride (TG) or re-esterified triglyceride (rTG) forms found in whole fish. Clinical data consistently show that re-esterified triglycerides achieve superior plasma and erythrocyte membrane incorporation compared to ethyl esters, yet many consumers ingest EE capsules in a fasted state or with low-fat breakfast, severely blunting systemic uptake [11,12,13].

Beyond the chemical form, individual genetic architecture significantly modulates omega-3 metabolism. Polymorphisms in the FADS1 and FADS2 gene clusters, which encode the delta-5 and delta-6 desaturase enzymes, dictate the rate at which plant-derived precursors are converted to longer-chain PUFAs and influence the handling of preformed EPA and DHA. Individuals carrying minor alleles for these variants may exhibit intrinsically lower baseline omega-3 status and a resistant response to standard supplementation protocols. Effectively requiring higher doses or specific phospholipid bound forms to achieve therapeutic levels [14,15,16].

Ultimately, the mere presence of EPA and DHA in the blood stream does not guarantee their functional integration into cell membranes. Incorporation into the phospholipid bilayer, the critical step for altering membrane fluidity and receptor signaling is a competitive and resource dependent process. Without the appropriate nutritional context, such as resource-dependent process. Without the appropriate nutritional context, such as adequate background dietary fats to facilitate chylomicron formation and transport, supplemental omega-3s may be oxidized for energy rather than esterified into membrane phospholipids. This failure of delivery explains why, for many, supplementation remains a “biological ghost”: present in the diet, but absent where it matters most, the cell membrane [17,18].

The Context Matters: Omega-6 Overload and Dietary Ratio Trap

The failure of omega-3 supplementation to consistently deliver clinical results is inextricably to the biochemical environment in which it enters: one dominated by an unprecedented surplus of omega-6 linoleic acid (LA). Modern industrial diets, rich in processed seeds oils (soybean, corn, sunflower), provide LA at levels historically alien to human physiology, often skewing the omega-6 to omega-3 ratio from an ancestral ~4:1 to a staggering 20:1 or higher. This omnipresent substrate does not merely coexist with omega-3s; it aggressively outcompetes them. Both omega-6 and omega-3 fatty acids rely on the same limited pool of desaturase and elongase enzymes (specifically D6- desaturase and D5-desaturase) for conversion into their biologically active long-chain forms. Because LA is consumed in such vast excess, often orders of magnitude higher than alpha-linolenic acid (ALA), it effectively monopolizes these enzymatic pathways, severely throttling the endogenous synthesis of EPA and DHA and impairing the incorporation of preformed omega-3s into cellular membranes [19,20,21,22,23].

This enzymatic hegemony has profound downstream consequences for eicosanoid signaling. When omega-6 arachidonic (AA) dominates membrane phospholipids, immune activation triggers the release of AA-derived lipid mediators, including pro-inflammatory prostaglandins (PGE2) and leukotrienes (LTB4). While these molecules are necessary for acute defense, their chronic overproduction drives systemic low-grade inflammation, vasoconstriction, and platelet aggregation. In contrast, omega-3s are the precursors to specialized pro-resolving mediators (SPMs) like resolvins and protectins, which are essential for turning off the inflammatory response [20,21,22,23,24].

In a high-omega-6 environment, this “off switch” is mechanically jammed. The overwhelming presence of omega-6 substrates not only fuels the pro-inflammatory fire but also competitively inhibits the production of the very molecules needed to extinguish it. Consequently, supplementation with standard doses of fish oil is often insufficient to overcome this competitive inhibition, leaving the body in a state of “non-resolving” inflammation where the resolution pathways remain biochemically silent despite the presence of therapeutic omega-3s [20,21,25].

The Oxidation Issue: Rancid Fats and Mitochondrial Stress

Perhaps the most insidious factor undermining omega-3 efficacy is the oxidative instability of the molecules themselves. The multiple double bonds that give EPA and DHA their fluidity and biological potency also make them exceptionally vulnerable to peroxidation, a process that can begin long before the capsule reaches the consumer. Independent analyses have repeatedly demonstrated that a significant proportion of commercially available fish oil supplements exceed international limits for primary and secondary oxidation products (peroxides and aldehydes) at the time of purchase. Once ingested, these pre-oxidized lipids do not merely lose their therapeutic value; they actively introduce a toxic burden. The gastric environment can further catalyze oxidation, generating reactive aldehydes such as 4-hydroxy-2-hexenal (4-HHE) and malondialdehyde (MDA), which are capable of covalently modifying proteins and DHA [26,27,28,29].

This influx of oxidized lipids (lipid peroxides) creates a paradoxical state where a “health” supplement becomes a driver of systemic oxidative stress. Upon absorption, these peroxidation products are incorporated into lipoproteins and cellular membranes, where they can initiate chain reactions that deplete endogenous antioxidants like glutathione and vitamin E. instead of resolving inflammation, the oxidized fatty acids can trigger endothelial activation and cytotoxicity, potentially accelerating the very atherosclerotic processes they are meant to prevent [30,31,32].

Crucially, this oxidative assault converges on the mitochondria. Mitochondrial membranes are highly enriched in phospholipids and are the primary site of cellular energy production, but they are also uniquely sensitive to lipid peroxidation. When oxidized omega-3 species integrate into mitochondrial membranes, they compromise the electron transport chain, increase proton leak, and amplify the production of mitochondrial reactive oxygen species (mtROS). In the context of metabolic disease, where mitochondrial are often already stressed, this additional oxidative load can exacerbate mitochondrial dysfunction, impair bioenergetics, and accelerate cellular senescence, thereby negating the intended longevity benefits and potentially fueling the “inflammaging” process [33,34,35,36,37,38].

The Missing Context of Metabolic Health

The expectation that omega-3 supplementation alone can reverse established pathology ignores the critical dependence of these lipids on the host’s metabolic terrain. In a state of profound metabolic inflexibility and insulin resistance, the cellular machinery required to properly utilize EPA and DHA is fundamentally compromised. Under conditions of hyperinsulinemia and excess caloric burden, mitochondrial function is impaired, often characterized by uncoupling and an inability to efficiently switch between fuel substrates. Consequently, introduced omega-3 fatty acids may be sequestered into ectopic lipid droplets or oxidized indiscriminately rather than being integrated into functional membrane microdomains. Crucially, omega-3s are not antidotes to the systemic oxidative burden generated by visceral adiposity and chronic hyperglycemia; instead, in a highly oxidative environment, the presence of these polyunsaturated fats can theoretically amplify lipid peroxidation if endogenous antioxidant defenses are already overwhelmed [39,40,41,42].

The biological mismatch offers a compelling explanation for the null results observed in major clinical trials such as the ORIGIN and Risk and prevention studies, which predominantly enrolled participants with long-standing type 2 diabetes, obesity, or advanced cardiovascular disease. In these cohorts, the metabolic “damage” defined by entrenched mitochondrial dysfunction and chronic low-grade inflammation may be too advanced for omega-3s to exert a rescue effect. The failure isn’t necessarily of the molecule, but of the timing: applying a subtle modulator of membrane fluidity to a system in metabolic crisis is akin to tuning an engine that is actively overheating [41,42,43].

Emerging evidence suggests that “metabolic readiness” is a prerequisite for omega-3 efficacy. Interventions that first restore insulin sensitivity and reduce oxidative stress such as time-restricted feeding, ketogenic metabolic switching, or exercise training, create a physiological context where omega-3s can be properly assimilated. For instance, exercise has been shown to synergize with fish oil to enhance mitochondrial fusion and fatty acid oxidation rates more effectively than either intervention alone. Thus, the future of omega-3 therapy likely lies not in higher doses, but in sequencing: establishing a foundation of metabolic flexibility allows these essential fats to fulfill their evolutionary role as signal transducers rather than mere fuel [44,45].

Quality, Timing, and Biological Synergy

The reductionist approach of isolating EPA and DHA into concentrated capsules often strips away the biological matrix that enhances their stability and function in nature. Research increasingly points to “nutrient synergy” as a critical determinant of efficacy, where omega-3s perform best when accompanied by specific co-factors. For example, polyphenols (such as those found in olive oil or berries) and lipophilic antioxidants like vitamin E protect polyunsaturated fatty acids from oxidation both in the gut and in the bloodstream, preserving their bioactivity until they reach target tissues. Similarly, magnesium and B-vitamins have been shown to support the enzymatic machinery required for fatty acid metabolism and neuroprotection, suggesting that a “cocktail” approach may yield superior outcomes compared to monotherapy [46,47,48,49].

This matrix effect is most evident when comparing food sources to processed supplements. Omega-3s in krill oil or egg yolks are predominantly bound to phospholipids, a form that mimics the structure of human cell membranes and utilizes different absorption pathways than the ethyl esters or triglycerides found in standard fish oils. This phospholipid carriage, often bypassing the need for bile-dependent emulsification, facilitates more efficient delivery of EPA and DHA to the brain and liver. Furthermore, whole food sources like sardines provide a complex nutritional milieu, including calcium, selenium, and taurine, which offer independent cardioprotective benefits and may synergistically enhance the anti-inflammatory index of the diet in ways that isolated supplements cannot replicate [50,51,52].

Finally, the “when” and “how” of consumption are as the “what.” Ingesting omega-3s in a fasted state or with a low-fat meal dramatically reduces absorption, whereas taking them alongside a meal containing fat activates the biliary secretion necessary for optimal uptake. Moreover, the inflammatory context of the meal matters: consuming omega-3s within a low-glycemic, low-omega-6 framework maximizes their potential to resolve inflammation, whereas adding them to a high-calorie, processed diet is biologically counterproductive. Thus, shifting the focus from high-dose supplementation to strategic integration, prioritizing phospholipid0rich sources, ensuring antioxidant protection, and timing intake with nutrient-dense meals, may be the key to unlocking the true therapeutic potential of these essential fats [7,51,53].

Rethinking Fat Balance in the Longevity Era

The future of omega-3 intervention lies not in single-nutrient megadosing, but in a system biology approach that prioritizes “membrane intelligence”, the capacity of cellular membranes to maintain optimal fluidity, signaling fidelity, and resilience against stress. This perspective aligns with the “membrane pacemaker” theory of aging, which posits that the fatty acid composition of cellular membranes is a fundamental determinant of metabolic rate, oxidative susceptibility, and ultimately, longevity. Rather than viewing omega-3s as pharmaceutical-like “fix” for specific symptoms, we must understand them as essential architects of the mitochondrial and plasma membranes. When these membranes are constructed with the correct balance of saturated, monounsaturated and polyunsaturated fats, they support efficient electron transport and minimize the “proton leak” that drives metabolic inefficiency and senescence.

This paradigm shift necessitates moving away from reductionist supplementation toward comprehensive food-pattern and lifestyle optimization. It acknowledges that the benefits of omega-3s are maximally realized only when the “oxidative terrain” is favorable, meaning a diet low in ultra0processed omega-6 seeds oils and high in varied antioxidant rich matrices. Recent data suggest that whole-food interventions, such as increasing fatty fish intake, often outperform isolated supplements in modulating lipid profiles and reducing inflammatory markers, likely due to the complex interplay of co-nutrients like selenium, vitamin D, and specialized pro-resolving mediator precursors found in the natural food matrix.

Ultimately, re-establishing this lipid balance is a cornerstone of mitigating “inflammaging”, the chronic, sterile inflammation that accelerates biological aging. By curating a cellular environment where omega-3s are protected from oxidation and efficiently incorporated into mitochondrial membranes, we can harness their potential to preserve bioenergetic function and delay the onset of age-related metabolic decline. In this context, omega-3s cease to be a simple supplement and become a critical tool for engineering a resilient, longevity-compatible phenotype.

Conclusion (Omega-3s Don’t Work Alone, They Work in Context)

The evidence presented throughout this review points to a fundamental reconceptualization: the failure of omega-3 supplementation is not a failure of the molecule itself, but rather a failure to account for the broader biochemical ecosystem in which these fatty acids must operate. Omega-3s are not panaceas; they are precise modulators of cellular and mitochondrial function that have been evolutionarily selected to work within a specific nutritional and lifestyle context. In the modern environment, one characterized by energy excess, omega-6 polyunsaturated fat overload, high oxidative stress from processed foods and sedentary living, and pervasive mitochondrial dysfunction, omega-3 supplementation alone becomes a symptom-focused intervention in the absence of foundational metabolic restoration.

A genuine shift toward metabolic integration requires addressing multiple pillars simultaneously. First and foremost, reducing dietary omega-6 burden by minimizing seed oil and ultra-processed food intake is not optional, it is a prerequisite. Clinical and experimental evidence demonstrates that lowering the omega-6: omega-3 ratio, whether through reducing linoleic acid intake or increasing preformed EPA/DHA, reduces oxidized metabolites of arachinoid acid, ameliorates hepatic steatosis, and suppresses inflammatory signaling. Second, restoring insulin sensitivity and metabolic flexibility through dietary intervention (such as lower-glycemic, nutrient-dense whole foods), strategic fasting protocols, and regular physical activity creates the mitochondrial and endocrine milieu necessary for omega-3s to be meaningfully incorporated rather than burned as fuel. Third, managing systemic oxidative stress through both lifestyle modifications which robustly improve superoxide dismutase and catalase activity, and judicious antioxidant support (via polyphenol-rich foods and targeted micronutrients) ensures that supplied omega-3s are protected from peroxidation and can fulfill their signaling functions.

The path forward is not the latest supplement formulation, but rather a return to metabolic fundamentals: a food pattern emphasizing whole sources of omega-3s, minimal seed oil exposure, abundant plant phytochemicals for antioxidant support, and the consistent activation of fat-oxidative and mitochondrial adaptive pathways through exercise and fasting. Within this integrated framework, omega-3s, whether from whole fish, phospholipid-rich sources, or carefully formulated supplements with appropriate antioxidant protection, become meaningful contributors to cardiovascular health, cognitive resilience, and longevity. The future of preventive metabolic medicine rests not on identifying newer molecules, but on constructing a biological foundation where the molecules we already know work optimally.

Reference

  1. Kar A, Ghosh P, Patra P, Chini DS, Nath AK, Saha JK, et al. Omega-3 fatty acids mediated Cellular signaling and its regulation in Human Health. Clinical Nutrition Open Science [Internet]. 2023 Dec 1;52:72–86. Available from: https://www.sciencedirect.com/science/article/pii/S266726852300058X
  2. Cawley J, Thow A, Wen K, Frisvold D. The Economics of Taxes on Sugar-Sweetened Beverages: A Review of the Effects on Prices, Sales, Cross-Border Shopping, and Consumption. 2019 [cited 2024 May 24]; Available from: https://www.annualreviews.org/docserver/fulltext/nutr/39/1/annurev-nutr-082018-124603.pdf?expires=1716510046&id=id&accname=guest&checksum=BFBF4B60CCAD62610F2D240C268D179F
  3. Li M, Li Z, Fan Y. Omega-3 fatty acids: multi-target mechanisms and therapeutic applications in neurodevelopmental disorders and epilepsy. Frontiers in Nutrition. 2025 May 30;12.
  4. Banaszak M, Małgorzata Dobrzyńska, Kawka A, Górna I, Dagmara Woźniak, Juliusz Przysławski, et al. Role of Omega-3 fatty acids eicosapentaenoic (EPA) and docosahexaenoic (DHA) as modulatory and anti-inflammatory agents in noncommunicable diet-related diseases – Reports from the last 10 years. Clinical Nutrition ESPEN. 2024 Oct 1;63:240–58.
  5. Kwon Y. Immuno‐Resolving Ability of Resolvins, Protectins, and Maresins Derived from Omega‐3 Fatty Acids in Metabolic Syndrome. Molecular Nutrition & Food Research. 2019 Dec 15;64(4):1900824.
  6. Specialized pro-resolving mediators – Knowledge and References | Taylor & Francis [Internet]. Taylor & Francis. 2021 [cited 2025 Dec 11]. Available from: https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Physiology/Specialized_pro-resolving_mediators/
  7. Kris-Etherton PM, Harris WS, Appel LJ. Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease. Circulation. 2002 Nov 19;106(21):2747–57.
  8. Jump DB, Depner CM, Tripathy S. Omega-3 fatty acid supplementation and cardiovascular disease. Journal of Lipid Research [Internet]. 2012 Dec 1;53(12):2525–45. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494243/
  9. Haq AD, Harahap HS, Wahyudi S, Susilawati NNA. SALTWATER FISH CONSUMPTION AND THE RISK OF STROKE IN COASTAL POPULATION. MNJ (Malang Neurology Journal). 2024 Jan 1;10(1):59–63.
  10. Harris WS, Tintle NL, Cornish L, Lin J. The Omega-3 Index is higher in people from a coastal town versus 5 inland US cities: An observational study. Nutrition Research [Internet]. 2022 Aug 1 [cited 2024 Mar 15];104:66–70. Available from: https://www.sciencedirect.com/science/article/pii/S0271531722000446
  11. Fish Oil Triglycerides vs. Ethyl Esters – Short Hills Ophthalmology [Internet]. Short Hills Ophthalmology. 2017. Available from: https://shorthillseye.com/blog/fish-oil-triglycerides-vs-ethyl-esters/
  12. Holub B, Grebow J. Omega-3 Bioavailability: Is One Form of Omega-3 More Bioavailable than Another? [Internet]. [cited 2025 Dec 11]. Available from: https://www.puroomega.com/wp-content/uploads/2016/06/Paper-2011-Omega-3-Bioavailabity-TG-vs-EE.pdf
  13. Dyerberg J, Madsen P, Møller JM, Aardestrup I, Schmidt EB. Bioavailability of marine n-3 fatty acid formulations. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2010 Sep;83(3):137–41.
  14. Associations of delta fatty acid desaturase gene polymorphisms with lipid metabolism disorders | Russian Open Medical Journal [Internet]. Romj.org. 2025 [cited 2025 Dec 11]. Available from: https://www.romj.org/2021-0403
  15. Chilton FH, Manichaikul A, Yang C, O’Connor TD, Johnstone LM, Blomquist S, et al. Interpreting Clinical Trials With Omega-3 Supplements in the Context of Ancestry and FADS Genetic Variation. Frontiers in Nutrition. 2022 Feb 8;8.
  16. Santana, Pereira M, Gisele Queiroz Carvalho, Maria, Iúri Drumond Louro, Santos, et al. FADS1 and FADS2 Gene Polymorphisms Modulate the Relationship of Omega-3 and Omega-6 Fatty Acid Plasma Concentrations in Gestational Weight Gain: A NISAMI Cohort Study. Nutrients. 2022 Mar 2;14(5):1056–6.
  17. Gerling CJ, Mukai K, Chabowski A, Heigenhauser GJF, Holloway GP, Spriet LL, et al. Incorporation of Omega-3 Fatty Acids Into Human Skeletal Muscle Sarcolemmal and Mitochondrial Membranes Following 12 Weeks of Fish Oil Supplementation. Frontiers in Physiology. 2019 Mar 29;10.
  18. Minton ST, Almada AL, Evans JL, Laidlaw M, Opheim J. Comparative membrane incorporation of omega-3 fish oil triglyceride preparations differing by degree of re-esterification: A sixteen-week randomized intervention trial. Traber MG, editor. PLOS ONE. 2023 Jan 27;18(1):e0265462.
  19. Sahu P, Abinash Satapathy, Abhisek Satapathy, Kumar A, Kumar M, Kashyap P, et al. Omega-3 Fatty Acids: From Natural Sources to Clinical Applications: An Integrative Review. Journal of Drug Delivery and Therapeutics. 2025 Nov 15;15(11):156–75.
  20. DiNicolantonio JJ, O’Keefe J. The Importance of Maintaining a Low Omega-6/Omega-3 Ratio for Reducing the Risk of Autoimmune Diseases, Asthma, and Allergies. Missouri Medicine [Internet]. 2021 Sep;118(5):453. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8504498/
  21. Mariamenatu AH, Abdu EM. Overconsumption of Omega-6 Polyunsaturated Fatty Acids (PUFAs) versus Deficiency of Omega-3 PUFAs in Modern-Day Diets: The Disturbing Factor for Their “Balanced Antagonistic Metabolic Functions” in the Human Body. Kostner GM, editor. Journal of Lipids. 2021 Mar 17;2021(1):1–15.
  22. Fritsche KL. Linoleic Acid, Vegetable Oils & Inflammation. Missouri Medicine [Internet]. 2014 Jan;111(1):41. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6179509/
  23. Mercola J, D’Adamo CR. Linoleic Acid: A Narrative Review of the Effects of Increased Intake in the Standard American Diet and Associations with Chronic Disease. Nutrients [Internet]. 2023 Jan 1;15(14):3129. Available from: https://www.mdpi.com/2072-6643/15/14/3129
  24. Wang B, Wu L, Chen J, Dong L, Chen C, Wen Z, et al. Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets. Signal Transduction and Targeted Therapy. 2021 Feb 26;6(1).
  25. Innes JK, Calder PC. Omega-6 fatty acids and inflammation. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2018 May;132:41–8.
  26. Soulage CO, Pelletier CC, Florens N, Lemoine S, Dubourg L, Juillard L, et al. Two Toxic Lipid Aldehydes, 4-hydroxy-2-hexenal (4-HHE) and 4-hydroxy-2-nonenal (4-HNE), Accumulate in Patients with Chronic Kidney Disease. Toxins. 2020 Sep 3;12(9):567.
  27. Martinsen B. Why Are Fish Oil Oxidation Values Important to Your Health? [Internet]. Omega3 Innovations. 2019 [cited 2025 Dec 11]. Available from: https://omega3innovations.com/blog/making-sense-of-fish-oil-oxidation-values/
  28. Hands JM, Anderson ML, Cooperman T, Frame LA. A Multi-Year Rancidity Analysis of 72 Marine and Microalgal Oil Omega-3 Supplements. Journal of Dietary Supplements. 2023 Sep 15;21(2):195–206.
  29. Larsson K, Tullberg C, Alminger M, Havenaar R, Undeland I. Malondialdehyde and 4-hydroxy-2-hexenal are formed during dynamic gastrointestinal in vitro digestion of cod liver oils. Food & Function. 2016 Aug 10;7(8):3458–67.
  30. Albert BB, Derraik JGB, Cameron-Smith D, Hofman PL, Tumanov S, Villas-Boas SG, et al. Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA. Scientific Reports. 2015 Jan 21;5(1).
  31. Peskin BS. Why Fish Oil Fails: A Comprehensive 21st Century Lipids-Based Physiologic Analysis. Journal of Lipids. 2014;2014:1–15.
  32. Soulage CO, Pelletier CC, Florens N, Lemoine S, Dubourg L, Juillard L, et al. Two Toxic Lipid Aldehydes, 4-hydroxy-2-hexenal (4-HHE) and 4-hydroxy-2-nonenal (4-HNE), Accumulate in Patients with Chronic Kidney Disease. Toxins. 2020 Sep 3;12(9):567.
  33. Yin P, Xie S, Huo Y, Guo T, Fang H, Zhang Y, et al. Effects of dietary oxidized fish oil on growth performance, antioxidant defense system, apoptosis and mitochondrial function of juvenile largemouth bass (Micropterus salmoides). Aquaculture. 2018 Sep 5;500:347–58.
  34. Zhang DG, Zhao T, Hogstrand C, Ye HM, Xu XJ, Luo Z. Oxidized fish oils increased lipid deposition via oxidative stress-mediated mitochondrial dysfunction and the CREB1-Bcl2-Beclin1 pathway in the liver tissues and hepatocytes of yellow catfish. Food Chemistry. 2021 Oct;360:129814.
  35. Champigny C, Cormier R, Simard C, Patrick-Denis St-Coeur, Fortin S, Pichaud N. Omega-3 Monoacylglyceride Effects on Longevity, Mitochondrial Metabolism and Oxidative Stress: Insights from Drosophila melanogaster. Marine Drugs. 2018 Nov 16;16(11):453–3.
  36. N Avramovic, V Dragutinovic, Krstic D, MB Colovic, A Trbovic, Luka S de, et al. The effects of omega 3 fatty acid supplementation on brain tissue oxidative status in aged wistar rats. Hippokratia [Internet]. 2022;16(3):241. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3738731/
  37. Zhang DG, Kunz WS, Lei XJ, Zito E, Zhao T, Xu YC, et al. Selenium Ameliorated Oxidized Fish Oil-Induced Lipotoxicity viathe Inhibition of Mitochondrial Oxidative Stress, Remodeling of Usp4-Mediated Deubiquitination, and Stabilization of Pparα. Antioxidants & Redox Signaling. 2024 Mar 1;40(7-9):433–52.
  38. Buck B. Omega-3 Fatty Acids, Inflammation, and Oxidative Stress in Aging Muscle [Internet]. Vibrant-wellness.com. Vibrant Wellness; 2025 [cited 2025 Dec 11]. Available from: https://vibrant-wellness.com/blog/omega-3-fatty-acids-inflammation-and-oxidative-stress-in-aging-muscle
  39. Sinha S, Haque M, Lugova H, Kumar S. The Effect of Omega-3 Fatty Acids on Insulin Resistance. Life [Internet]. 2023 Jun 1;13(6):1322. Available from: https://www.mdpi.com/2075-1729/13/6/1322
  40. Krupa K, Fritz K, Parmar M. Omega-3 Fatty Acids [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK564314/
  41. Lepretti M, Martucciello S, Burgos Aceves M, Putti R, Lionetti L. Omega-3 Fatty Acids and Insulin Resistance: Focus on the Regulation of Mitochondria and Endoplasmic Reticulum Stress. Nutrients [Internet]. 2018 Mar 14;10(3):350. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872768/
  42. Albert BB, Cameron-Smith D, Hofman PL, Cutfield WS. Oxidation of Marine Omega-3 Supplements and Human Health. BioMed Research International [Internet]. 2013;2013:1–8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3657456/
  43. Siscovick DS, Barringer TA, Fretts AM, Wu JHY, Lichtenstein AH, Costello RB, et al. Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease. Circulation [Internet]. 2017 Apr 11;135(15). Available from: https://www.ahajournals.org/doi/10.1161/cir.0000000000000482
  44. Jansen KM, Moreno S, Garcia-Roves PM, Larsen TS. Dietary Calanus oil recovers metabolic flexibility and rescues postischemic cardiac function in obese female mice. American Journal of Physiology-Heart and Circulatory Physiology. 2019 Aug 1;317(2):H290–9.
  45. Logan SL, Spriet LL. Omega-3 Fatty Acid Supplementation for 12 Weeks Increases Resting and Exercise Metabolic Rate in Healthy Community-Dwelling Older Females. Nishi D, editor. PLOS ONE. 2015 Dec 17;10(12):e0144828.
  46. Hrebień‐Filisińska A. Application of natural antioxidants in the oxidative stabilization of fish oils: A mini‐review. Journal of Food Processing and Preservation. 2021 Feb 16;
  47. Méndez L, Medina I. Polyphenols and Fish Oils for Improving Metabolic Health: A Revision of the Recent Evidence for Their Combined Nutraceutical Effects. Molecules [Internet]. 2021 Apr 22;26(9). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122614/
  48. Businaro R. Food supplements to complement brain functioning: the benefits of a combination of magnesium, folic acid, omega-3 fatty acids and vitamin E. F1000Research. 2022 Feb 3;11(1):140.
  49. Pietro Barbacini, Dieter Blottner, Capitanio D, Trautmann G, Block K, Torretta E, et al. Effects of Omega-3 and Antioxidant Cocktail Supplement on Prolonged Bed Rest: Results from Serum Proteome and Sphingolipids Analysis. Cells. 2022 Jul 5;11(13):2120–0.
  50. Schuchardt J, Schneider I, Meyer H, Neubronner J, von Schacky C, Hahn A. Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations – a comparative bioavailability study of fish oil vs. krill oil. Lipids in Health and Disease [Internet]. 2011 [cited 2019 Aug 8];10(1):145. Available from: https://lipidworld.biomedcentral.com/articles/10.1186/1476-511X-10-145
  51. Santos HO, May TL, Bueno AA. Eating more sardines instead of fish oil supplementation: Beyond omega-3 polyunsaturated fatty acids, a matrix of nutrients with cardiovascular benefits. Frontiers in Nutrition. 2023 Apr 14;10.
  52. Ulven SM, Holven KB. Comparison of bioavailability of krill oil versus fish oil and health effect. Vascular Health and Risk Management. 2015 Aug;511.
  53. Angélica Borja-Magno, Guevara-Cruz M, Flores-López A, Carrillo-Domínguez S, Granados J, Arias C, et al. Differential effects of high dose omega-3 fatty acids on metabolism and inflammation in patients with obesity: eicosapentaenoic and docosahexaenoic acid Frontiers in Nutrition. 2023 May 5;10.